CVnCoV

BIOLOGICAL2 trials

Sponsors

CureVac, Masaryk University

Conditions

Adverse Reaction to VaccineCOVID19 VaccineCovid19SARS-CoV-2

Phase 2

A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

CompletedNCT04652102

CureVacCovid19, SARS-CoV-2

Start: 2020-12-11End: 2022-06-10Updated: 2024-04-29

Unknown Phase

COVID-19 Vaccines Safety Tracking (CoVaST)

RecruitingNCT04834869

Masaryk UniversityAdverse Reaction to Vaccine, COVID19 Vaccine

Start: 2021-04-01End: 2026-12-31Target: 30000Updated: 2022-04-06

Related Papers

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.

2021-11-23136 citations

COVID-19 Vaccines Safety Tracking (CoVaST): Protocol of a Multi-Center Prospective Cohort Study for Active Surveillance of COVID-19 Vaccines’ Side Effects

International Journal of Environmental Research and Public Health2021-07-2568 citations

International COVID-19 Vaccines Safety Tracking Study (CoVaST-RU): Participation of the Russian Federation

Russian Journal of Preventive Medicine2021-01-011 citations